CordenPharma Astorg Switzerland

CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry's most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements.View original content:https://www.prnewswire.co.uk/news-releases/cordenpharma-invests-900m-in-transformational-peptide-platform-expansion-in-the-usa--europe-302197452.html